TSLA
Tesla
-- 383.465 NVDA
NVIDIA
-- 137.850 PLTR
Palantir
-- 75.030 RGTI
Rigetti Computing
-- 17.5550 MSTR
MicroStrategy
-- 301.868 
NEWS
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
Unicycive Therapeutics (UNCY) presented multiple studies at ASN Kidney Week 2024, highlighting progress on oxylanthanum carbonate (OLC) and UNI-494. The late-breaking presentation showed OLC enabled serum phosphate control in >90% of chronic kidney disease patients on dialysis who entered maintenance phase, with 69% achieving target levels at ≤1500 mg/day. The company also presented positive Phase 1 safety data for UNI-494. Two recent publications featured preclinical studies for both compounds. OLC demonstrated synergistic effects when combined with tenapanor in rat studies, while UNI-494 showed potential in treating acute kidney injury.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment